Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.35 |
| ▸ | BRAF | P15056 | 10/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208269 | 0.90 | RAF1 (0.37) | RAF1BRAF | |
| SCHEMBL3211787 | 0.89 | AURKA (0.35) | RAF1BRAFHIF1AEPAS1CNR2 | |
| SCHEMBL3197206 | 0.88 | RAF1 (0.42) | RAF1BRAFHIF1AEPAS1CNR2 | |
| SCHEMBL197313 | 0.85 | FLT3 (0.38) | RAF1BRAFHIF1AEPAS1CNR2 | |
| SCHEMBL3217181 | 0.84 | FLT3 (0.36) | RAF1BRAFHIF1AEPAS1CDK8 | |
| SCHEMBL3205822 | 0.82 | MAPK14 (0.38) | HIF1AEPAS1CSF1RFLT3 | |
| SCHEMBL13495532 | 0.82 | HIF1A (0.34) | RAF1BRAFHIF1AEPAS1CCNC | |
| SCHEMBL3197187 | 0.80 | RAF1 (0.34) | RAF1BRAFABL1 | |
| SCHEMBL3214407 | 0.79 | RAF1 (0.35) | RAF1BRAF | |
| SCHEMBL3214469 | 0.79 | RAF1 (0.34) | RAF1BRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | RAF1 74/4885BRAF 79/4885HIF1A 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.